Policy Developments - The National Health Commission will hold a press conference on November 27, 2025, to discuss the progress and effectiveness of grassroots medical and health services [1] Industry Initiatives - Beijing's Economic and Information Technology Bureau, along with six departments, has introduced measures to accelerate the promotion of artificial intelligence-assisted diagnostic technologies, including financial support of up to 50 million yuan for selected projects [2] Regulatory Approvals - Saikexide has obtained registration for three medical device products, enhancing its product range in the in vitro diagnostic field [3] - Xinhua Pharmaceutical has received a drug registration certificate for a compound local anesthetic cream, with an estimated sales revenue of 615 million yuan in 2024 [4] - Heng Rui Medicine has received approval for clinical trials of its innovative anti-tumor drug HRS-8364, with a cumulative R&D investment of approximately 21.65 million yuan [5] Capital Market Activities - Suzhou High-tech plans to sell a 47% stake in its medical device subsidiary for 604 million yuan [6] - Shanghai DeYin Technology has completed a Pre-A round financing of several million yuan, backed by listed company Songlin Technology [8] Industry News - Novartis China has responded to rumors of dissolving its county-level team, stating it will adjust its operational model while continuing to serve the county medical market [9] - Samsung Medical's subsidiary has been recommended as a candidate for a procurement project with a total expected amount of approximately 107 million yuan [10] Legal Matters - Foreign companies have filed a Section 337 investigation request against specific antibody-drug conjugates, alleging infringement of trade secrets, involving companies from the US, Netherlands, and China [11] Shareholder Actions - Bid Pharma's shareholder plans to reduce their stake by up to 0.16% between December 17, 2025, and March 16, 2026, due to funding needs [12]

Core Points - The company has recently obtained medical device registration certificates for three products from the Beijing Drug Administration, enhancing its product offerings in the in vitro diagnostic field [1][4] - The acquisition of these certificates is expected to strengthen the company's competitive position and improve its market expansion capabilities by meeting diverse clinical needs [1] Medical Device Registration Details - The specific details of the medical device registration certificates were not disclosed in the announcement [1] Impact on the Company - The new medical device registration certificates will enrich the company's product variety and expand its presence in the in vitro diagnostics sector, which is anticipated to enhance overall competitiveness [1]

Legal Issues - Danghong Technology is involved in a lawsuit with Guangxi Broadcasting Network Technology Development Co., Ltd., with a counterclaim amounting to RMB 35.9495 million, excluding legal fees and other costs [3] - Zhangjiajie faces a court ruling in a contract dispute with Zhuzhou CRRC Engineering, with the amount in question being RMB 20.144 million plus related penalties [12] Regulatory Actions - Keres received an administrative regulatory decision from the Guangdong Securities Regulatory Bureau for violations related to accounts receivable aging calculations and related party transactions [4] Business Developments - Dongfang Yuhong acquired mining rights for limestone in a bid worth RMB 267 million, valid from November 24, 2025, to November 24, 2045 [5] - Saikexide has received approval for three medical device products, enhancing its product range in the in vitro diagnostics sector [6] - Huayou Cobalt signed a supply agreement with Yiwei Lithium Energy for high-nickel ternary cathode materials, with an estimated supply of 127,800 tons from 2026 to 2035 [7] Stock Performance and Corporate Actions - Mengtian Home experienced a five-day stock price increase, with a total rise of 61.08%, significantly outpacing the Shanghai Composite Index [9] - Jiumuwang's stock showed abnormal fluctuations, with a revenue decline of 6.02% year-on-year for the first three quarters [10] - Huafeng shares are suspended due to a potential change in control, with a stock suspension expected to last no more than three trading days [11] - Baiyun Electric conducted its first share buyback, acquiring 86,500 shares for a total of RMB 1.0034 million [13] - Mercury Home Textiles plans to repurchase and cancel 137,200 restricted shares due to employee departures and performance issues [14] - Petty Co. announced a share buyback plan of RMB 50 million to 70 million, with a maximum price of RMB 26 per share [15] - Century Huatong obtained a loan commitment of up to RMB 900 million from China Merchants Bank for stock repurchase purposes [17] Shareholding Changes - Tongding Interconnection's major shareholder plans to reduce its stake by up to 0.49% [18] - Wanrun Co.'s controlling shareholder plans to increase its stake by no less than RMB 365 million and no more than RMB 730 million [19]

证券日报网讯11月25日晚间，赛科希德发布公告称，公司3个医疗器械产品已获批注册。 ...

分组1 - Weili Medical plans to distribute a cash dividend of 2 yuan per 10 shares to all shareholders, based on an undistributed profit of 704 million yuan as of September 30, 2025 [1] - Tongding Interconnect's shareholder plans to reduce their stake by up to 0.49%, equating to a maximum of 605,800 shares [1] - Caitong Securities has received approval from the China Securities Regulatory Commission to issue short-term corporate bonds with a total face value of up to 5 billion yuan [1] 分组2 - Youfu Food intends to use 70 million yuan of its own funds to invest in wealth management products with expected annual returns of up to 4.2% [3] - Keres received an administrative regulatory decision from the Guangdong Securities Regulatory Bureau for violations related to accounts receivable aging calculations and related party transactions [5] - Ouma Software's controlling shareholder has completed the transfer of state-owned equity, changing the controlling shareholder to Shandong Guotou [7] 分组3 - ST Huapeng's wholly-owned subsidiary has completed a major overhaul project and is now in production [8] - Beiqi Blue Valley has received approval from the China Securities Regulatory Commission for a stock issuance to specific investors [8] - Weijie Chuangxin received a government subsidy of 5 million yuan, accounting for 21.07% of its projected net profit for 2024 [9] 分组4 - China Resources Double Crane's subsidiary has received a drug registration certificate for a hypertension treatment drug [11] - Huafeng shares are continuing to suspend trading due to a planned change in control [13] - Kaifa Electric's shareholder plans to transfer 36.6869 million shares, representing 11.63% of the total share capital [14] 分组5 - Heng Rui Medicine has received approval for two clinical trials for innovative anti-tumor drugs [15] - Kosen Technology plans to invest 30 million USD to establish a new production base in Malaysia [17] - Sanxing Medical's subsidiary is expected to win a procurement project from the State Grid worth approximately 107 million yuan [18] 分组6 - Sitai Li's subsidiary has received a drug registration certificate for a contrast agent used in MRI [21] - Daren Tang's subsidiary has received a drug registration certificate for a pain relief gel [22] - Saike Xide has received approval for three medical device products, expanding its product range in the in vitro diagnostic field [23] 分组7 - Hasa Lian has elected a new chairman and vice chairman for its board of directors [24] - Two-sided Needle's subsidiary plans to invest 68.8522 million yuan in a production base expansion project [25] - Sunshine Nuohe plans to transfer 70% of its controlling subsidiary's equity for 2 million yuan [26] 分组8 - Hengbang shares received an administrative regulatory decision from the Shandong Securities Regulatory Bureau for failing to complete the election of independent directors [27] - Huali shares plan to sign a related transaction contract worth approximately 59.2847 million yuan [28] - Shangwei shares plan to invest 520.4 million yuan to gain a controlling stake in Sichuan Zhongfu Taihua [30] 分组9 - Zejing Pharmaceutical's ZG006 has been included in the list of breakthrough therapeutic varieties for treating advanced neuroendocrine cancer [32] - Yaopi Glass's shareholder plans to reduce their stake by up to 2.26%, equating to a maximum of 21.1469 million shares [34] - Huate Gas has initiated a major lawsuit involving a claim of 180 million yuan [36] 分组10 - Zhongchumei's controlling shareholder plans to increase their stake by between 42 million and 80 million yuan [37] - Huitong shares' shareholder plans to reduce their stake by up to 1% [38] - Miaowei Exhibition plans to apply for an initial public offering of H shares on the Hong Kong Stock Exchange [40] 分组11 - Tianqi Lithium's subsidiary has appealed to the Chilean Supreme Court regarding a partnership agreement with SQM and Codelco [42] - Naxin Micro plans to repurchase shares worth between 200 million and 400 million yuan [44] - Pingao shares have reported significant uncertainty regarding future business development and profitability [46] 分组12 - Shunyu shares have been pre-selected for a project worth 1.023 billion yuan [48] - Zhongyuan Neipei plans to acquire a 2.5% share in an aerospace industry fund for 50 million yuan [50] - Huifa Food's shareholder plans to reduce their stake by up to 3%, equating to a maximum of 727.14 million shares [53] 分组13 - Junshi Biosciences' subcutaneous PD-1 new formulation has reached its primary endpoint in a Phase III clinical trial [54] - Industrial Fulian clarified that it has not lowered its fourth-quarter profit target amid market rumors [55] - Longpan Technology's subsidiary has signed a major supply agreement for lithium iron phosphate materials, significantly increasing the supply volume [56]

Group 1 - Donghong Technology is involved in a lawsuit with a claim amounting to RMB 35.95 million, with some bank accounts frozen totaling RMB 30 million, and actual frozen funds of RMB 20.84 million [1] - Keres received an administrative regulatory decision from the Guangdong Securities Regulatory Commission for violations related to accounts receivable aging calculation, related party transaction disclosure, fundraising management, and insider information management [2] - Oriental Yuhong successfully bid RMB 267 million for mining rights, valid from November 24, 2025, to November 24, 2045 [3] Group 2 - Saikexide has received approval for three medical device products, enhancing its product range and competitiveness in the in vitro diagnostics field [4] - Huayou Cobalt signed a supply agreement with Yiwei Lithium Energy for high-nickel ternary cathode materials, expected to supply approximately 127,800 tons from 2026 to 2035 [5] - Meng Tian Home's stock price has hit the limit for five consecutive trading days, with a total increase of 61.08%, significantly deviating from the Shanghai Composite Index's decline of 1.77% during the same period [6] Group 3 - Jiumuwang's stock experienced abnormal fluctuations, with a revenue decline of 6.02% year-on-year for the first three quarters of 2025, totaling RMB 633.13 million [7] - Huafeng Co. announced a continued suspension of trading due to a planned change in control, with the suspension expected to last no more than three trading days [8] - Zhangjiajie is involved in a court case with Zhuzhou CRRC Engineering, with a judgment amount of RMB 20.14 million, including penalties and related fees [9] Group 4 - Baiyun Electric conducted its first share buyback, acquiring 86,500 shares for a total of RMB 1.0034 million [11] - Mercury Home Textiles plans to repurchase and cancel 137,200 restricted shares due to the departure of two incentive targets and underperformance of five others [12] - Petty Co. approved a share buyback plan of RMB 50 million to 70 million, with a maximum price of RMB 26 per share, aimed at employee stock ownership plans [13] Group 5 - Century Huatong obtained a commitment letter from China Merchants Bank for a stock buyback loan of up to RMB 900 million, valid for 12 months [14] - Tongding Interconnection announced a major shareholder's plan to reduce holdings of up to 605,800 shares due to personal funding needs [15] - Wanrun Co.'s controlling shareholder plans to increase its stake in the company by investing between RMB 365 million and 730 million over the next six months [16]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京赛科希德科技股份有限公司（以下简称"公司"）于近期从北京市药品 监督管理局（以下简称"北京药监局"）网站 http://yjj.beijing.gov.cn/信 息查询获悉，公司 3 个医疗器械产品已获批注册，具体情况如下： 证券代码：688338 证券简称：赛科希德 公告编号：2025-050 北京赛科希德科技股份有限公司 关于自愿披露取得医疗器械注册证的公告 上述注册证的取得仅代表公司相关产品获得国内市场准入资格，产品上市后 的实际销售情况取决于未来市场的推广效果，目前尚无法预测上述产品对公司未 来业绩的具体影响。敬请投资者理性投资，注意投资风险。 特此公告。 | 序 号 | 产品名称 | | 注册证编号 | 注册证有效期 | | 注册 分类 | 适用范围/预期用途 | | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | 抗Ⅹa 剂盒（发色底 | 测定试 | 京械注准 | 2025-11-24 | 至 | Ⅱ ...

Core Viewpoint - The company has recently received approval for three medical device products from the Beijing Drug Administration, indicating a positive development in its product portfolio [1] Group 1 - The approved products include: Anti-Xa assay kit (colorimetric substrate method), Anti-Xa calibrator, and Anti-Xa quality control products [1]

Core Viewpoint - The company has recently received approval for three medical device products from the Beijing Drug Administration, indicating a positive development in its product portfolio [1] Group 1 - The approved products include: Anti-Xa assay kit (color substrate method), Anti-Xa calibrator, and Anti-Xa quality control products [1]

Meeting Overview - The second extraordinary general meeting of shareholders was held on November 21, 2025, at the company's conference room in Beijing [2] - The meeting was convened by the board of directors and chaired by Chairman Wu Shiming, utilizing a combination of on-site and online voting methods [2] Attendance - All 9 serving directors attended the meeting, with independent director Jiang Zheming participating via telecommunication [3] - All 3 serving supervisors were present, along with the board secretary and several deputy general managers [3] Resolutions Passed - The proposal to abolish the supervisory board and amend the Articles of Association was approved [4] - Multiple governance documents were revised and approved, including: - Amendments to the Rules of Procedure for Shareholders' Meetings [5] - Amendments to the Rules of Procedure for Board Meetings [5] - Amendments to the Compensation Management System for Directors, Supervisors, and Senior Management [5] - Amendments to the Independent Director System [5] - Amendments to the External Investment Management Measures [5] - Amendments to the Related Party Transaction Management Measures [5] - Amendments to the Financing and External Guarantee Management Measures [5] - Amendments to the Management System for Raised Funds [5] - The abolition of the Rules of Procedure for Supervisory Meetings and the Implementation Details of Cumulative Voting System for Shareholders' Meetings was also approved [6] Voting Details - The first proposal required a special resolution, needing more than two-thirds of the voting rights held by attending shareholders to pass, while other proposals required a simple majority [6] - Separate counting of votes was conducted for the first proposal concerning minority investors [6] Legal Verification - The meeting was witnessed by Beijing Zhonglun Law Firm, with lawyers confirming that the meeting's procedures and resolutions complied with legal and regulatory requirements [6]